http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 20 May 2026 07:01:09 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/4basebio+secures+clinical+supply+deal+for+Phase+II+cancer+trial/26524661.html <p>4basebio PLC (AIM: 4BB) announced it has signed a clinical supply agreement with an oncology-focused biotechnology company to provide synthetic DNA material for a Phase II immunotherapy clinical trial.</p> <p>Under the agreement, 4basebio will supply GMP-grade opDNA starting material using its enzymatic DNA synthesis technology. The company expects the deal to generate approximately seven-figure revenue over the next 12 months.</p> <p>The client will use 4basebio's synthetic DNA as a critical component for its immunotherapy candidate in the upcoming Phase II trial. The company's enzymatic, cell-free manufacturing process eliminates microbial contamination and antibiotic resistance genes compared to traditional plasmid DNA production methods.</p> <p>"This partnership http://www.streetinsider.com/Corporate+News/4basebio+secures+clinical+supply+deal+for+Phase+II+cancer+trial/26524661.html Wed, 20 May 2026 07:01:09 -0400 4BB A.01476324 A.32383221 O.00004430 O.01236171 O.51169219 http://www.streetinsider.com/Corporate+News/4basebio+secures+clinical+supply+deal+for+Phase+II+cancer+trial/26524661.html <p>4basebio PLC (AIM: 4BB) announced it has signed a clinical supply agreement with an oncology-focused biotechnology company to provide synthetic DNA material for a Phase II immunotherapy clinical trial.</p> <p>Under the agreement, 4basebio will supply GMP-grade opDNA starting material using its enzymatic DNA synthesis technology. The company expects the deal to generate approximately seven-figure revenue over the next 12 months.</p> <p>The client will use 4basebio's synthetic DNA as a critical component for its immunotherapy candidate in the upcoming Phase II trial. The company's enzymatic, cell-free manufacturing process eliminates microbial contamination and antibiotic resistance genes compared to traditional plasmid DNA production methods.</p> <p>"This partnership http://www.streetinsider.com/Corporate+News/4basebio+secures+clinical+supply+deal+for+Phase+II+cancer+trial/26524661.html Wed, 20 May 2026 07:01:09 -0400 4BB A.01476324 A.32383221 O.00004430 O.01236171 O.51169219 http://www.streetinsider.com/Corporate+News/4basebio+secures+clinical+supply+deal+for+Phase+II+cancer+trial/26524661.html <p>4basebio PLC (AIM: 4BB) announced it has signed a clinical supply agreement with an oncology-focused biotechnology company to provide synthetic DNA material for a Phase II immunotherapy clinical trial.</p> <p>Under the agreement, 4basebio will supply GMP-grade opDNA starting material using its enzymatic DNA synthesis technology. The company expects the deal to generate approximately seven-figure revenue over the next 12 months.</p> <p>The client will use 4basebio's synthetic DNA as a critical component for its immunotherapy candidate in the upcoming Phase II trial. The company's enzymatic, cell-free manufacturing process eliminates microbial contamination and antibiotic resistance genes compared to traditional plasmid DNA production methods.</p> <p>"This partnership http://www.streetinsider.com/Corporate+News/4basebio+secures+clinical+supply+deal+for+Phase+II+cancer+trial/26524661.html Wed, 20 May 2026 07:01:09 -0400 4BB A.01476324 A.32383221 O.00004430 O.01236171 O.51169219 http://www.streetinsider.com/Corporate+News/4basebio+secures+clinical+supply+deal+for+Phase+II+cancer+trial/26524661.html <p>4basebio PLC (AIM: 4BB) announced it has signed a clinical supply agreement with an oncology-focused biotechnology company to provide synthetic DNA material for a Phase II immunotherapy clinical trial.</p> <p>Under the agreement, 4basebio will supply GMP-grade opDNA starting material using its enzymatic DNA synthesis technology. The company expects the deal to generate approximately seven-figure revenue over the next 12 months.</p> <p>The client will use 4basebio's synthetic DNA as a critical component for its immunotherapy candidate in the upcoming Phase II trial. The company's enzymatic, cell-free manufacturing process eliminates microbial contamination and antibiotic resistance genes compared to traditional plasmid DNA production methods.</p> <p>"This partnership http://www.streetinsider.com/Corporate+News/4basebio+secures+clinical+supply+deal+for+Phase+II+cancer+trial/26524661.html Wed, 20 May 2026 07:01:09 -0400 4BB A.01476324 A.32383221 O.00004430 O.01236171 O.51169219 http://www.streetinsider.com/Corporate+News/4basebio+secures+clinical+supply+deal+for+Phase+II+cancer+trial/26524661.html <p>4basebio PLC (AIM: 4BB) announced it has signed a clinical supply agreement with an oncology-focused biotechnology company to provide synthetic DNA material for a Phase II immunotherapy clinical trial.</p> <p>Under the agreement, 4basebio will supply GMP-grade opDNA starting material using its enzymatic DNA synthesis technology. The company expects the deal to generate approximately seven-figure revenue over the next 12 months.</p> <p>The client will use 4basebio's synthetic DNA as a critical component for its immunotherapy candidate in the upcoming Phase II trial. The company's enzymatic, cell-free manufacturing process eliminates microbial contamination and antibiotic resistance genes compared to traditional plasmid DNA production methods.</p> <p>"This partnership http://www.streetinsider.com/Corporate+News/4basebio+secures+clinical+supply+deal+for+Phase+II+cancer+trial/26524661.html Wed, 20 May 2026 07:01:09 -0400 4BB A.01476324 A.32383221 O.00004430 O.01236171 O.51169219 http://www.streetinsider.com/Corporate+News/4basebio+secures+clinical+supply+deal+for+Phase+II+cancer+trial/26524661.html <p>4basebio PLC (AIM: 4BB) announced it has signed a clinical supply agreement with an oncology-focused biotechnology company to provide synthetic DNA material for a Phase II immunotherapy clinical trial.</p> <p>Under the agreement, 4basebio will supply GMP-grade opDNA starting material using its enzymatic DNA synthesis technology. The company expects the deal to generate approximately seven-figure revenue over the next 12 months.</p> <p>The client will use 4basebio's synthetic DNA as a critical component for its immunotherapy candidate in the upcoming Phase II trial. The company's enzymatic, cell-free manufacturing process eliminates microbial contamination and antibiotic resistance genes compared to traditional plasmid DNA production methods.</p> <p>"This partnership http://www.streetinsider.com/Corporate+News/4basebio+secures+clinical+supply+deal+for+Phase+II+cancer+trial/26524661.html Wed, 20 May 2026 07:01:09 -0400 4BB A.01476324 A.32383221 O.00004430 O.01236171 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Press+Releases/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Globe+Newswire/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Globe+Newswire/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Globe+Newswire/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Globe+Newswire/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219 http://www.streetinsider.com/Globe+Newswire/Final+Results+and+Notice+of+AGM/26524635.html <p><b>CAMBRIDGE, UK – 20 May</b> <b>2026</b> <b>–</b> 4basebio plc (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.</p> <p><b>FINANCIAL HIGHLIGHTS</b></p> <ul type="disc"><li style="text-align:justify;">Revenue for the period of £1.7 million (FY 2024: £0.9 million), representing growth of 81%, with revenue from clinical stage projects contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue increasing by 100%</li><li style="margin-top:12pt; text-align:justify;">Loss for the period of £16.9 million (FY 2024: £12.3 million), reflecting continued planned investment in commercial infrastructure, GMP capabilities and http://www.streetinsider.com/Globe+Newswire/Final+Results+and+Notice+of+AGM/26524635.html Wed, 20 May 2026 07:00:00 -0400 4BB A.01476324 A.17190303 A.31508783 A.32383221 A.39807895 A.50216015 A.50216242 O.00004430 O.01236171 O.22244327 O.39706357 O.45226484 O.49014974 O.49194046 O.51169219